Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma

Strahlentherapie und Onkologie

Volumn 184, Issue 11, 2008, Pages 572-579

  Kocher, Martin ^a   Frommolt, Peter ^a   Borberg, Sigrid Klara ^b   Rühl, Ursula ^c   Steingräber, Maria ^d   Niewald, Markus ^e   Staar, Susanne ^f   Stuschke, Martin ^g   Becker, Gerd ^h   Fischedick, Arnt René ⁱ   Herfarth, Klaus ^j   Grauthoff, Hermann ^f   Müller, Rolf Peter ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b Gemeinschaftspraxis for Radiation Oncology and Radiotherapy   (Germany)

^c VIVANTES KLINIKUM IM FRIEDRICHSHAIN   (Germany)

^d VIVANTES KLINIKUM NEUKÖLLN   (Germany)

^e SAARLAND UNIVERSITY   (Germany)

^f Zentralkrankenhaus ^*  (Germany)

^g UNIVERSITY HOSPITAL ESSEN   (Germany)

^h KLINIK AM EICHERT   (Germany)

ⁱ Clemenshospital Munster   (Germany)

^j UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

more..

Author keywords

Glioblastoma; Irradiation; Malignant glioma; Quality of life; Radiochemotherapy; Temozolomide

Indexed keywords

TEMOZOLOMIDE;

ADJUVANT THERAPY; ADULT; ARTICLE; BACTERIAL INFECTION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; GLIOBLASTOMA; HUMAN; INTERMETHOD COMPARISON; LARYNX EDEMA; LEUKOPENIA; LUNG EMBOLISM; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MENINGOENCEPHALITIS; MYASTHENIA; NAUSEA; NEUTROPENIA; PATIENT COMPLIANCE; QUALITY OF LIFE; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SIDE EFFECT; SOMNOLENCE; THROMBOCYTOPENIA; VIRUS INFECTION;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BLOOD CELL COUNT; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE-FREE SURVIVAL; ETHICS, MEDICAL; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT SELECTION; QUALITY OF LIFE; RADIOTHERAPY DOSAGE; SALVAGE THERAPY; SURVIVAL ANALYSIS;

EID: 56549091495     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-008-1897-0     Document Type: Article

References (31)

1. Athanassiou H, Synodinou M, Maragoudakis E, et al. Randomised phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol 2005;23:2372-77.
2. Brada M, Ashley S, Dowe A, et al. Neoadjuvant phase II multicentre study of new agents in patients with malignant glioma after minimal surgery. Report of a cohort of 187 patients treated with temozolomide. Ann Oncol 2005;16:942-9.
3. Brandes AA, Tosoni A, Spagnolli F, et al. Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. Neuro Oncol 2008;10:361-7.
4. Cahill DP, Levine KK, Betensky RA, et al. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res 2007;13:2038-45.
5. Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 2006;24:2707-14.
6. Caroli M, Locatelli M, Campanella R, et al. Temozolomide in glioblastoma: results of administration at first relapse and in newly diagnosed cases. Is still proposable an alternative schedule to concomitant protocol? J. Neurooncol 2007;84:71-7.
7. Chakravarti A, Erkkinen MG, Nestler U, et al. Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. Clin Cancer Res 2006;12:4738-46.
8. Chamberlain MC, Glantz MJ, Chalmers L, et al. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 2007;82:81-3.
9. Corsa P, Parisi S, Raguso A, et al. Temozolomide and radiotherapy as first-line treatment of high-grade gliomas. Tumori 2006;92:299-305.
10. De Sanctis V, Mazzarella G, Osti MF, et al. Radiotherapy and sequential temozolomide compared with radiotherapy with concomitant and sequential temozolomide in the treatment of newly diagnosed glioblastoma multiforme. Anticancer Drugs 2006;17:969-75.
11. Fisher T, Galanti G, Lavie G, et al. Mechanisms operative in the antitumor activity of temozolomideZ in glioblastoma multiforme. Cancer J 2007;13:335-44.
12. Gorlia T, Van den Bent MJ, Hegi ME, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981. Lancet Oncol 2008;9:29-38.
13. Ishii D, Natsume A, Wakabayashi T, et al. Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acis repair gene MGMT in malignant gliomas. Neurol Med Chir (Tokyo) 2007;47:341-9.
14. Kocher M, Kunze S, Eich HT, Semrau R and Müller RP. Efficacy and toxicity of postoperative temozolomide radiochemotherapy in malignant glioma. Strahlenther Onkol 2005;181:157-63.
15. Kong DS, Lee JI, Kim WS, et al. A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma. Oncol Rep 2006;16:1117-21.
16. Krengli M, Loi G, Sacchetti G, et al. Delineation of target volume for radiotherapy of high-grade gliomas by 99m Tc-MIBI SPECT and MRI fusion. Strahlenther Onkol 2007;183:689-94.
17. Mineo JF, Bordron A, Baroncini M, et al. Prognosis factors of survival time in patients with glioblastoma multiforme: a multivariate analysis. Acta Neurochir (Wien) 2007;149:245-52.
18. Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: Recursive partitioning analysis of the EORTC 26981/22981 - NCIC CE3 phase III randomized trial. J Clin Oncol 2006;24:2563-69.
19. Oertel S, Krempien R, Lindel K, et al. Human glioblastoma and carcinoma xenograft tumors treated by combined radiation and imatinib (Gleevec). Strahlenther Onkol 2006;182:400-7.
20. Piroth M, Gagel B, Pinkawa M, et al. Postoperative radiotherapy of glioblastoma multiforme: analysis and critical assessment of different treatment strategies and predictive factors. Strahlenther Onkol 2007;183:695-702.
21. Schuuring J, Bussink J, Bernsen H, et al. Effect of carbogen breathing on the radiation response of a human glioblastoma xenograft: analysis of hypoxia and vascular parameters of regrowing tumors. Strahlenther Onkol 2006;182:408-14.
22. Spiegel BM, Esrailian E, Laine L, et al. Clinical impact of adjuvant chemotherapy in glioblastoma multiforme: a meta-analysis. CNS Drugs 2007;21:775-87.
23. Stupp R, Dietrich P-Y, Kraljevic SO, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002;20:1375-82.
24. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant TMZ for glioblastoma. N Engl J Med 2005;352:987-96.
25. Taphoorn MJ, Stupp R, Coens C, et al. Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol 2005;6:937-44.
26. Tselis N, Kolotas C, Birn G, et al. CT-guided interstitial HDR brachytherapy for recurrent glioblastoma multiforme. Long-term results. Strahlenther Onkol 2007;183:563-70.
27. Valeriani M, Ferretti A, Franzese P, et al. High-grade gliomas: results in patients treated with adjuvant radiotherapy alone and with adjuvant radiochemotherapy. Anticancer Res 2006;26:2429-35.
28. van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 2006;24:2715-22.
29. Van Rijn J, Heimans JJ, Van den Berg J, et al. Survival of human glioma cells treated with various combination of temozolomide and x-rays. Int J Radiat Oncol Biol Phys 2000;47:779-84.
30. Wemmert S, Ketter R, Rahnenführer J, et al. Patients with high-grade gliomaa harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment. Neoplasia 2005;7:883-93.
31. Wick A, Felsberg J, Steinbach JP, et al. Efficacy and tolerability of temozolomide in an alternative weekly regimen in patients with recurrent glioma. J Clin Oncol 2007;25:3357-61.